Intravitreal injection (IVI) of anti‐VEGF drugs is a standardised therapy currently used for the treatment of DME, other diabetes‐related diseases (wet age‐related macular degeneration, proliferative diabetic retinopathy), retinal vein occlusion, and non‐age‐related macular neovascularization (inflammatory, post‐traumatic, etc.)[1]. The gene discussed is VEGFA; the disease is retinal vein occlusion.